REGISTER
China-Made First-in-Class Drug From Huahui Health Approved for the First Time
Libevitug, Huahui Health’s neutralizing antibody targeting the PreS1 domain of the HBV/HDV large envelope protein, has been approved in China for chronic hepatitis D virus infection, offering a new treatment option for one of the most severe forms of viral hepatitis.

On January 23, the NMPA website showed that Huahui Health’s libevitug (HH-003) had been approved as a new drug for the treatment of chronic hepatitis D virus (HDV) infection. The drug had previously been included in the priority review pathway by the Center for Drug Evaluation (CDE) and had received breakthrough therapy designation from both the CDE and the FDA for HDV infection.

Libevitug is the world’s first neutralizing antibody targeting the pre-S1 region of the large envelope protein of hepatitis B/hepatitis D virus developed by Huahui Health. By specifically binding the PreS1 region on the surface of HBV/HDV, it blocks binding between HBV, HDV, and the NTCP receptor, thereby preventing viral entry into hepatocytes and neutralizing infection.

At the 2025 annual meeting of the American Association for the Study of Liver Diseases (AASLD), Huahui Health presented the latest breakthrough abstract as an oral presentation, disclosing 48-week clinical data from the pivotal registrational Phase IIb study HH003-204 (NCT05861674) in chronic HDV infection.

HH003-204 is an international, multicenter, randomized, controlled, open-label pivotal trial evaluating the efficacy and safety of different doses of libevitug in people with chronic HDV infection. The primary efficacy endpoint was composite response, defined as the proportion of subjects at Week 24 with HDV RNA below the lower limit of quantification or reduced by at least 2 log10 from baseline, together with ALT normalization.

The trial showed that libevitug delivered statistically significant and clinically meaningful efficacy versus the control group in composite endpoint response, virologic suppression, ALT normalization, and improvement in liver stiffness in patients with chronic HDV infection. Both libevitug treatment groups also showed good tolerability and an excellent safety profile during the 48-week treatment period.

At Week 24, the composite response rates in both libevitug dose groups were significantly higher than in the control group. In the 20 mg/kg and 10 mg/kg groups, 35.0% (14/40) and 32.4% (11/34) of subjects, respectively, achieved the primary endpoint, compared with only 5.0% (1/20) in the control group.

At Week 48, the composite response rates increased further to 42.5% in the 20 mg/kg group and 44.1% in the 10 mg/kg group, while the control group remained at 5.0%.

Chronic hepatitis D is the most severe form of viral hepatitis. According to World Health Organization (WHO) estimates, 15 million to 20 million people worldwide live with chronic HDV infection. The disease progresses rapidly and often develops into cirrhosis, liver cancer, and other serious liver diseases. Today’s approval of libevitug will provide a new treatment option for these patients.

0
0
Loading